Acino has signed an exclusive licensing agreement with Bioprojet, to register, market, commercialise, and distribute an innovative medicine in Saudi Arabia, with potential expansion to other countries in the Middle East.
For licensing, manufacturing, and supply of select Acino products across the Kingdom
Acino and Alpha Pharma will further the goals of Saudi Arabia’s Health Sector Transformation Programme
This acquisition complements our growth ambitions for South Africa and fortifies our investment in the country.
The most beautiful thing is to look back and see what we have achieved together and then take the momentum with us to grow further.